More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune Knowpia

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

§ Target Disease Indication

Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Lupus Nephritis
Melanoma
Multiple Myeloma
Primary Sjögren's Syndrome
Others

§ Target Immune Checkpoint

B7-H3
CD38
CD40
CD47
Others

§ Mechanism of Action

Inhibitory
Stimulatory

§ Therapeutic Modality

Monoclonal Antibody
Small Molecule

§ Type of Therapy

Monotherapy
Combination Therapy

§ Route of Administration

Intravenous
Subcutaneous
Others

§ Key Geographical Regions

North America
Europe
Asia-Pacific and the Rest of the World

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain:

§ Bristol Myers Squibb

§ GlaxoSmithKline

§ Incyte

§ Novartis

§ Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape: Clinical and Preclinical Molecules

5. Market Landscape: Therapies Targeting Cd47

6. Market Landscape: Therapies Targeting 4-1bb

7. Clinical Trial Analysis